QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.
The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.
Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.
QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.
The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.
Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.
Why choose us?
Customer satisfaction is our absolute priority
Your timeline is our timeline
Every study is custom-built
Scientific input to study design and data interpretation
Extensive experience with virtually all drug targets and treatment types
Wide range of validated models and techniques for comprehensive compound tests from a single source
AAALAC certification ensures highest quality standards
QPS NEURO NEWS
Interested in plaque-associated inflammation?
Interested in plaque-associated inflammation?
QPS Neuropharmacology is your partner for visualization and quantification of plaque-associated inflammation. Figure 1 shows an exemplary quantification process to evaluate microglia (Iba1 labeled) adjacent to amyloid-beta plaques (6E10 labeled).
Multichannel immunofluorescence (up to four different antibodies plus DAPI labeling in one experiment), whole-slide imaging, and quantitative image analysis, allows detailed evaluation of pathological changes.
The image analysis is macro-based using Image-Pro 10 software, enabling fast and cost-efficient quantification of large batches of images. Importantly, the results are operator-independent and fully reproducible.
Figure 1: Immunolabeling of 10 month old 5xFAD mouse brain section and the analysis process to quantify plaque-associated microglial activation. A: Merged signal of amyloid-beta (6E10 in red) and microglia (Iba1 in white); cell nuclei are labeled with DAPI (blue). B-D: Single channel images of 6E10. Scale bar: 50 µm. (B), Iba1 (C), and DAPI (D). E-I: Quantification process: First, 6E10-immunoreactive positive objects (plaques) are identified by adequate thresholding and morphological filtering (E). Second, mask images of the evaluated 6E10-positive area are created (F) and the borders of 6E10-positive objects are extended by 15 µm in all directions (G, H). Finally, Iba1-positive objects (activated microglia) are quantified in the vicinity of amyloid-beta plaques (I).
Meet us at the AAIC 2019 conference in Los Angeles, California, USA
The QPS Austria Neuropharmacology team will attend the Alzheimer’s Association International Conference 2019 and are pleased to meet you at our booth # 212.
Additionally, our scientists are presenting our newest research results in four posters:
14th of July
P1-112: „PROGRESSIVE INCREASE OF ALZHEIMER’S DISEASE PATHOLOGY IN 5XFAD TRANSGENIC MICE” Tina Loeffler, Magdalena Temmel, Jörg Neddens, Irene Schilcher, Birgit Hutter-Paier.
16th of July
P3-113: “UNTANGLING ALZHEIMER´S DISEASE HALLMARKS IN SENSORY SYSTEMS OF RODENT MODELS” ” Joerg Neddens, Magdalena Temmel, Meritxell Aguilo Garcia, Tina Loeffler, Irati Aiestaran Zelaia, Vera Niederkofler, Stefanie Flunkert, Birgit Hutter-Paier.
17th of July
P4-061“TAU PHOSPHORYLATION PROFILE OF HTAU TRANSGENIC MICE” ” Joerg Neddens, Tina Loeffler, Magdalena Temmel, Irene Schilcher, David Amschl, Birgit Hutter-Paier
P4-062: “IN VITRO MODELS TO STUDY TAU AGGREGATION, PHOSPHORYLATION AND UPTAKE” ” Tina Loeffler, Irene Schilcher, Stefanie Flunkert, Birgit Hutter-Paier
Join us from July 14-18 in the Los Angeles Convention Center, California, USA
Webinar “Predictive Disease Models for CNS Drug Development“
In November 2018, Birgit Hutter-Paier, PhD, the Director of Neuropharmacology at QPS Austria presented this webinar about validated transgenic and non-transgenic in vitro and in vivo models covering most targets of AD, PD, HD and other neurodegenerative diseases.
 |
You will learn:
|
Brought to you by ADDF ACCESS, a program of the ADDF and Science Exchange, as part of their commitment to connect researchers developing CNS drugs with technologies that can help accelerate breakthrough discoveries.
Format: 30 minutes with 10 minutes Q&A
In Vitro Services
QPS Austria’s Neuropharmacology Department provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.
In Vivo Services
We have more than 15 years experience in generating, characterizing and maintaining transgenic disease models and using them for drug testing projects. Several customized behavioral tests, including motor, cognitive, and emotional assays, are offered to phenotype mouse and rat models and to evaluate effects of compounds in different in vivo models.
Ex Vivo Services
Our ex vivo services cover a full range of histological services, a biobank composed of various specimen derived from our in-house in vivo and in vitro models, and numerous well established tests for biomarkers. We are happy to test new protocols and establish new markers to meet your specific needs.